Show channels:
All channels
Bladder cancer
Brain and spinal
Breast cancer
Cervical
Colon & rectal
Dermatological
General Information
Gynecological
Head and Neck
Kidney/adrenal
Liver
Lung
Lymphoma
Multiple Myeloma
Myelodysplastic syndromes
Myeloproliferative disorders
Pancreas
Pediatric
Prostate
Sarcoma
Stomach
Testicular
Thyroid
Upper aerodigestive
Found 15790 articles
Cytoskeleton-associated protein 4 (CKAP4) promotes malignant progression of human gliomas through inhibition of the Hippo signaling pathway.
CKAP4 highly upregulated in glioma.
»
04/02/21
A Novel Prediction Model for Colon Cancer Recurrence Using Auto-artificial Intelligence.
Auto-AI prediction model demonstrates improved accuracy.
»
07/09/21
Dietary Factors and Gastric Intestinal Metaplasia Risk Among US Veterans.
Associations primarily seen in non-White patients.
»
12/13/19
Fibrin/fibrinogen Degradation Products Are Associated With Tumor Stage and Prognosis in Patients Undergoing Resection of Esophageal Cancer.
Increased FDP level and pathological tumor depth independent prognostic factors for overall survival.
»
06/05/21
The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC).
Individual mutations mirrored response to therapy/progression of disease.
»
03/28/21
Cholesterol lowering drug use and breast cancer survival: the Multiethnic Cohort Study.
Improved survival associated with CLD use prior to diagnosis.
»
06/01/21
Prognostic Value of Preoperative Albumin-to-Fibrinogen Ratio in Patients with Bladder Cancer.
Preoperative AFR identified as independent prognostic predictor for OS.
»
03/30/21
Importance of Circ0009910 in colorectal cancer pathogenesis as a possible regulator of miR-145 and PEAK1
Statistically significant correlations observed between expression levels of circ0009910, miR-145-5p, and PEAK1.
»
09/03/21
Forecasting lung cancer incidence, mortality, and prevalence to year 2030
Numbers of prevalent cases of lung cancer in Denmark most likely will increase.
»
09/03/21
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
5-year disease-free survival (DFS) and disease-specific survival (DSS) rates 46.3% and 51.4%, respectively.
»
09/02/21
< Prev
Next >